

SUPPLEMENTARY DATA

Supplementary Table 1. Insulin Antibodies (%B/T)

Week		IDeg(A)	IDeg(B)
Cross-reacting antibodies* (%B/T)			
0	n	57	60
	Median (min-max)	4.5 (0 – 68.3)	4.5 (-0.1 – 53.7)
18	n	55	59
	Median (min-max)	8.5 (0.6 – 70.8)	6.1 (0 – 72.1)
IDeg-specific antibodies (%B/T)			
0	n	59	60
	Median (min-max)	-0.2 (-2.0 – 1.5)	-0.2 (-1.0 – 5.8)
18	n	55	60
	Median (min-max)	-0.2 (-1.9 – 2.4)	-0.2 (-1.4 – 1.7)
IAsp-specific antibodies (%B/T)			
0	n	58	60
	Median (min-max)	0.7 (-0.1 – 14.6)	0.9 (-0.8 – 17.8)
18	n	55	60
	Median (min-max)	0.9 (-0.2 – 14.3)	0.7 (-0.5 – 17.4)

* antibodies cross-reacting between IDeg and IAsp; n: number of subjects; %B/T: percent bound over total; IGlac-specific antibodies were not measured in this trial.

Supplementary Table 2. List of Principle Investigators

Country	Principle Investigators
Australia	Murray Gerstman, Andrew Lowy, Robert G. Moses, Geoffrey Nicholson and Anthony P. Roberts
Germany	Gerhard Klausmann, Stephan Maxeiner, Karsten Milek, Andrea Mölle, Alexander Segner and Ulrich Wendisch
Norway	Marianne C. Astor, Kåre I. Birkeland, Stefnir Gudnason, Mikkel Høiberg, Sverre Madsbu and Svein Skeie
Sweden	Ann-Sofie Bolmér, Peter Fors, Johan Jendle, Per-Eric Lins, Mona Landin-Olsson
United States	Ronald Brazg, David Fitz-Patrick, Gregory Peterson, Robert Ratner, Michael Reeves and Julio Rosenstock

SUPPLEMENTARY DATA

Supplementary Figure 1. Mean 9-point SMPG Profiles at baseline (Panel A) and after 16 weeks of treatment (Panel B).

